Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

Rapamycin / Sirolimus.

Research draft

Rapamycin, also called sirolimus, is a prescription mTOR inhibitor.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Rapamycin, also called sirolimus, is a prescription mTOR inhibitor.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It affects mTOR signalling involved in immune function, cell growth and metabolism.

Human research

Approved medical uses and exploratory ageing studies address different populations. Human lifespan extension is not established.

Preclinical & other research

Animal ageing research provides an important hypothesis, not a proven human anti-ageing benefit.

Safety & unknowns

Infection risk, mouth ulcers, lipid changes and impaired wound healing are relevant.

Regulatory status

Approved indications are product-specific; off-label longevity use is not an approved indication.

Reported use & evidence

Research profile draft

The supplied Rapamycin / Sirolimus profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds